Autoimmunity in scleroderma: The origin, pathogenetic role, and clinical significance of autoantibodies

Michelle L. Harris, Antony Rosen

Research output: Contribution to journalArticle

Abstract

Purpose of review: Systemic sclerosis, or scleroderma, is a systemic autoimmune disease manifest by vascular damage and fibrosis within the skin and visceral organs. Whereas scleroderma is a heterogenous disorder in terms of disease symptoms and clinical course, scleroderma-specific autoantibody profiles associate strongly with distinct clinical phenotypes, making serologic testing of great diagnostic aid. This review will focus on the clinical significance and the potential pathogenic role of autoantibodies in scleroderma. Recent findings: Novel autoantibody and phenotype associations discovered within the past year underscore the clinical utility of systemic sclerosis-associated autoantibodies. Whereas autoantibodies are generally believed to indicate the presence of ongoing tissue damage, some research suggests that the humoral immune response may play a role in generating such damage. Summary: Improvements in multiplex autoantibody assays will aid in the diagnosis and prognosis of the complications associated with systemic sclerosis. Continued research into autoantibody/phenotype associations could also yield critical insights into the pathogenesis of, and suggest novel therapeutic targets for, this chronic, debilitating disease.

Original languageEnglish (US)
Pages (from-to)778-784
Number of pages7
JournalCurrent Opinion in Rheumatology
Volume15
Issue number6
DOIs
StatePublished - Nov 2003

Fingerprint

Autoimmunity
Autoantibodies
Systemic Scleroderma
Phenotype
Humoral Immunity
Research
Autoimmune Diseases
Blood Vessels
Fibrosis
Chronic Disease
Skin

Keywords

  • Autoantibody
  • Pathogenesis
  • Scleroderma
  • Systemic sclerosis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Autoimmunity in scleroderma : The origin, pathogenetic role, and clinical significance of autoantibodies. / Harris, Michelle L.; Rosen, Antony.

In: Current Opinion in Rheumatology, Vol. 15, No. 6, 11.2003, p. 778-784.

Research output: Contribution to journalArticle

@article{ccd2f3e09a034bcfbc79ba051a2e412c,
title = "Autoimmunity in scleroderma: The origin, pathogenetic role, and clinical significance of autoantibodies",
abstract = "Purpose of review: Systemic sclerosis, or scleroderma, is a systemic autoimmune disease manifest by vascular damage and fibrosis within the skin and visceral organs. Whereas scleroderma is a heterogenous disorder in terms of disease symptoms and clinical course, scleroderma-specific autoantibody profiles associate strongly with distinct clinical phenotypes, making serologic testing of great diagnostic aid. This review will focus on the clinical significance and the potential pathogenic role of autoantibodies in scleroderma. Recent findings: Novel autoantibody and phenotype associations discovered within the past year underscore the clinical utility of systemic sclerosis-associated autoantibodies. Whereas autoantibodies are generally believed to indicate the presence of ongoing tissue damage, some research suggests that the humoral immune response may play a role in generating such damage. Summary: Improvements in multiplex autoantibody assays will aid in the diagnosis and prognosis of the complications associated with systemic sclerosis. Continued research into autoantibody/phenotype associations could also yield critical insights into the pathogenesis of, and suggest novel therapeutic targets for, this chronic, debilitating disease.",
keywords = "Autoantibody, Pathogenesis, Scleroderma, Systemic sclerosis",
author = "Harris, {Michelle L.} and Antony Rosen",
year = "2003",
month = "11",
doi = "10.1097/00002281-200311000-00016",
language = "English (US)",
volume = "15",
pages = "778--784",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Autoimmunity in scleroderma

T2 - The origin, pathogenetic role, and clinical significance of autoantibodies

AU - Harris, Michelle L.

AU - Rosen, Antony

PY - 2003/11

Y1 - 2003/11

N2 - Purpose of review: Systemic sclerosis, or scleroderma, is a systemic autoimmune disease manifest by vascular damage and fibrosis within the skin and visceral organs. Whereas scleroderma is a heterogenous disorder in terms of disease symptoms and clinical course, scleroderma-specific autoantibody profiles associate strongly with distinct clinical phenotypes, making serologic testing of great diagnostic aid. This review will focus on the clinical significance and the potential pathogenic role of autoantibodies in scleroderma. Recent findings: Novel autoantibody and phenotype associations discovered within the past year underscore the clinical utility of systemic sclerosis-associated autoantibodies. Whereas autoantibodies are generally believed to indicate the presence of ongoing tissue damage, some research suggests that the humoral immune response may play a role in generating such damage. Summary: Improvements in multiplex autoantibody assays will aid in the diagnosis and prognosis of the complications associated with systemic sclerosis. Continued research into autoantibody/phenotype associations could also yield critical insights into the pathogenesis of, and suggest novel therapeutic targets for, this chronic, debilitating disease.

AB - Purpose of review: Systemic sclerosis, or scleroderma, is a systemic autoimmune disease manifest by vascular damage and fibrosis within the skin and visceral organs. Whereas scleroderma is a heterogenous disorder in terms of disease symptoms and clinical course, scleroderma-specific autoantibody profiles associate strongly with distinct clinical phenotypes, making serologic testing of great diagnostic aid. This review will focus on the clinical significance and the potential pathogenic role of autoantibodies in scleroderma. Recent findings: Novel autoantibody and phenotype associations discovered within the past year underscore the clinical utility of systemic sclerosis-associated autoantibodies. Whereas autoantibodies are generally believed to indicate the presence of ongoing tissue damage, some research suggests that the humoral immune response may play a role in generating such damage. Summary: Improvements in multiplex autoantibody assays will aid in the diagnosis and prognosis of the complications associated with systemic sclerosis. Continued research into autoantibody/phenotype associations could also yield critical insights into the pathogenesis of, and suggest novel therapeutic targets for, this chronic, debilitating disease.

KW - Autoantibody

KW - Pathogenesis

KW - Scleroderma

KW - Systemic sclerosis

UR - http://www.scopus.com/inward/record.url?scp=0742287033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0742287033&partnerID=8YFLogxK

U2 - 10.1097/00002281-200311000-00016

DO - 10.1097/00002281-200311000-00016

M3 - Article

C2 - 14569210

AN - SCOPUS:0742287033

VL - 15

SP - 778

EP - 784

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

IS - 6

ER -